SUMMARY The circulating levels of hyaluronate were determined in 36 patients with scleroderma and in 36 control subjects matched for age and sex. The mean serum hyaluronate concentration in patients with progressive systemic sclerosis (n=25) was 131±67 (SD) ,g/l and significantly greater (p<0001) than that of the controls (mean level 49±21 (SD) pg/i). Hyaluronate levels in patients with localised scleroderma (n=4) were 141±47 (SEM) pg/l and in patients with scleroderma-associated overlap syndromes (n=7) 202±54 (SEM) [ig/l. The increase in serum hyaluronate probably reflected an enhanced synthesis or outflow of hyaluronate from the connective tissue, or both; it could not be explained by affection of the liver, which is the catabolic site of hyaluronate. The hyaluronate values were not related to certain serological indicators of inflammatory activity or to the extent of the skin lesions or the severity of internal organ manifestations. A positive correlation was noted between circulating platelet counts and hyaluronate levels (p<0-001). Plasma ,3-thromboglobulin was measured in 15 of the patients with systemic sclerosis and found to correlate positively with platelet counts. Raised levels of 3-thromboglobulin were associated with the highest hyaluronate values. Platelet-derived growth factor, which stimulates connective tissue cells and is stored in the a-granules of platelets together with ,-thromboglobulin, was shown to enhance hyaluronate synthesis in fibroblast cultures. The results suggest an involvement in scleroderma of connective tissue activating substances released from platelets.
hyaluronate'5 has enabled its determination not only in plasma or serum but in various biological fluids and tissue samples. '5'8 In the present work this method was applied to the determination of circulating hyaluronate levels in scleroderma, and to a study of whether raised levels correlated with the severity or progress of the disease.
Patients and methods PATIENT DATA Thirty-six inpatients with sclerodermatous skin changes were included in the study. They had a mean age of 52 years and a mean disease duration of 7*5 years. Twenty-five patients qualified for the diagnosis of progressive systemic sclerosis (PSS) .19 Four patients suffered from morphea, i.e., a purely dermatological affection with no systemic component. Seven patients possessed clinical hallmarks common to PSS but showed high antibody titres against extractable nuclear antigen and met the clinical criteria for mixed connective tissue disease (MCTD) established by Sharp.20 At the time of blood collection 11 of the patients with PSS were treated with cyclofenil 100-500 mg/day, alone or in combination with prednisolone (n=5) 2-5-10 mg/day. Two patients received penicillamine 500 mg/day, and another two received prednisolone 5-7-5 mg/day as the only drug. Ten patients were without drug treatment, as were all patients with morphea. One patient with MCTD was treated with prednisolone 7 
IN-VITRO EXPERIMENTS
The clinical evidence for increased platelet activity in scleroderma and the fact that platelets contain the growth factors PDGF and EGF acting on mesenchymal cells induced us to test whether these factors influenced the synthesis of hyaluronate. Incubation of human foreskin fibroblasts with PDGF or EGF in a completely synthetic medium caused an increase in hyaluronate accumulation both in the medium (3-7-5-2-fold stimulation) and in the cell layer (trypsin fraction; 1-6-1*7-fold stimulation) (Table 3) . Since there was an increase in the total amount of hyaluronate in the cultures, the observed effect was ascribed to an increase in the net synthesis of hyaluronic acid in the presence of the growth factors, rather than to a shift in distribution of hyaluronic acid between different compartments of the culture. Determination of hyaluronate after shorter periods of stimulation showed an increase in hyaluronic acid production at 20 h but not at 8 h (Fig. 2) .
Discussion
The present findings of raised serum levels of hyaluronate in progressive systemic scleroderma are in accordance with previous ideas of disturbed glycosaminoglycan metabolism in this disease. 
